GCLP

Nucleai and GoPath Diagnostics Announce Strategic Collaboration to Provide Integrated AI-powered Digital Pathology Solutions for Clinical Research and Diagnostic Applications

Retrieved on: 
Monday, April 8, 2024
Other Health, Software, Research, Pharmaceutical, Oncology, Technology, Artificial Intelligence, Genetics, Health Technology, Science, Biotechnology, Health, College, GCP, LMS, Algorithm, Prostate cancer, Case management, Good clinical laboratory practice, Partnership, LIMS, CLEP, Biomarker, GCLP, AI, CAP, Good clinical practice, IBD, Medicine, Workflow, CLIA, Pathology, Inflammatory bowel disease, Medical director, Medical device

Nucleai , a spatial AI biomarker company that deciphers cellular conversations and maps cellular interactions within tissue samples to predict therapeutic outcomes, today announced a strategic collaboration with GoPath Diagnostics , a leading full-service digital pathology and molecular diagnostics laboratory.

Key Points: 
  • Nucleai , a spatial AI biomarker company that deciphers cellular conversations and maps cellular interactions within tissue samples to predict therapeutic outcomes, today announced a strategic collaboration with GoPath Diagnostics , a leading full-service digital pathology and molecular diagnostics laboratory.
  • This partnership unites Nucleai and GoPath's complementary skills to expedite the development of new AI-powered clinical research and diagnostics.
  • The integrated solutions will be deployed within a centralized environment that meets the standards of the College of American Pathologists (CAP), Clinical Laboratory Improvement Amendments (CLIA), Clinical Laboratory Evaluation Program (CLEP), Good Clinical Practice (GCP), and Good Clinical Laboratory Practice (GCLP).
  • Jim Lu, M.D., CEO and Medical Director for GoPath Diagnostics, said: “Our collaboration with Nucleai transforms our capabilities, enabling GoPath to deliver a seamlessly integrated lab workflow.

GCCL Wins Top 10 Bioanalytical Services Providers in APAC 2023

Retrieved on: 
Monday, November 20, 2023
Ministry, Biology, Collection, Clinical trial, GCLP, Good clinical laboratory practice, Science, City, Thermo Fisher Scientific, Dementia, LIMS, Pharmaceutical industry, Food

YONGIN, South Korea, Nov. 20, 2023 /PRNewswire/ -- GCCL, a Korean clinical trial sample analysis company, announced on November 20th that it has been selected as the Top 10 Bioanalytical Services Providers in APAC 2023 awarded by Life Science Review, a U.S. business and technology magazine that focuses on the life science industry.

Key Points: 
  • YONGIN, South Korea, Nov. 20, 2023 /PRNewswire/ -- GCCL, a Korean clinical trial sample analysis company, announced on November 20th that it has been selected as the Top 10 Bioanalytical Services Providers in APAC 2023 awarded by Life Science Review, a U.S. business and technology magazine that focuses on the life science industry.
  • Life Science Review publishes articles covering the advances in the fields of science, technology and solutions, biology, and more.
  • This achievement signifies the uniqueness and efficiency of the company's bioanalytical services that are based on the adoption of various analytical platforms.
  • Song Hyun Yang, Ph.D. CEO of GCCL says, "We have embraced cutting-edge technology, implementing Thermo Fisher's LIMS to streamline analysis management.

Ozette Announces New Suite of Machine Learning-Powered Computational Analysis Solutions Coupled with High Dimensional Full Spectrum Cytometry Data Generation to Accelerate Decision-Making for Clinical Biomarker Teams

Retrieved on: 
Thursday, May 18, 2023
Health, Genetics, Clinical Trials, Research, Science, Biotechnology, Research fellow, GCLP, Biomarker, Assay, Patient, Immune system, Biology, Entrepreneurship, FDA, News, Disease, Data science, Medical imaging, Pharmaceutical industry

Ozette Assay-to-Insights combines three technologies developed by the company: world-class data generation at the Ozette Laboratory under Good Clinical Laboratory Practices (GCLP) guidelines; rapid computational monitoring of pre-defined biomarker endpoints using Ozette Endpoints™; and unbiased discovery and annotation of single-cell cytometry data through Ozette Discovery™.

Key Points: 
  • Ozette Assay-to-Insights combines three technologies developed by the company: world-class data generation at the Ozette Laboratory under Good Clinical Laboratory Practices (GCLP) guidelines; rapid computational monitoring of pre-defined biomarker endpoints using Ozette Endpoints™; and unbiased discovery and annotation of single-cell cytometry data through Ozette Discovery™.
  • Insights generated from Ozette Endpoints™ and Ozette Discovery™ are made available through the Ozette Platform™, a cloud-based system that enables clinical teams to interact and explore cytometry data in a central dashboard.
  • Ozette Endpoints™ provides clinical biomarker teams with rapid access to decision-enabling data.
  • Ozette Discovery™ provides best-in-class, unbiased, robust, and transparent automated cell population discovery and annotation from single-cell cytometry data.

Virscio Announces Launch of Pathology and Tissue Pharmacodynamics Services Division

Retrieved on: 
Wednesday, March 8, 2023
Other Health, Research, Pharmaceutical, Optical, Oncology, Clinical Trials, Science, Biotechnology, Stem Cells, FDA, Other Science, Health, GCLP, Immunohistochemistry, GLP, Toxicology, Pharmacokinetics, Investment, Histology, Doctor of Philosophy, Marie Cassidy, Safety, DVM, Pharmaceutical industry, Medical imaging, Pathology

Virscio, a leading provider of translational research and development services, announces the launch of a new Pathology and Tissue Pharmacodynamics Division to complement existing preclinical capabilities and further enable the timely execution, impact, and success of preclinical drug development programs.

Key Points: 
  • Virscio, a leading provider of translational research and development services, announces the launch of a new Pathology and Tissue Pharmacodynamics Division to complement existing preclinical capabilities and further enable the timely execution, impact, and success of preclinical drug development programs.
  • The Pathology and Tissue Pharmacodynamic division will be led by Dr. Jennifer Cann, DVM, PhD, Director of Pathology, and Richard Bouffard, Histology Director.
  • "We are excited to launch our Pathology and Tissue Pharmacodynamic Division and provide clients and collaborators an expanded suite of services to support their preclinical drug development programs," said Dr. Matthew Lawrence, Chief Executive Officer of Virscio Corporation.
  • "We are dedicated to further positioning Virscio as a premier translational R&D services organization, and the launch of our Pathology and Tissue Pharmacodynamic Division is a significant step toward that goal."

Bioanalytical Testing Services Market Worth $7.65 Billion by 2030: Grand View Research, Inc.

Retrieved on: 
Tuesday, October 18, 2022
Molecule, SAN, Revenue, Sony NEX-7, AstraZeneca, Small, GSK, Growth, Vaccine, Organization, CAGR, LC-MS, Bioavailability, GCLP, Services marketing, GlaxoSmithKline, COVID-19, Overalls, Good clinical laboratory practice, COVID-19 vaccine, USD, Fine chemical, Generic drug, Pharmaceutical industry, Bioequivalence, Workflow

Read 165-page market research report, " Bioanalytical Testing Services Market Size, Share & Trends Analysis Report By Molecule (Small, Large), By Test (Bioavailability, Bioequivalance), By Workflow (Sample Analysis, Sample Preparation), And Segment Forecasts, 2022 - 2030 ", published by Grand View Research.

Key Points: 
  • Read 165-page market research report, " Bioanalytical Testing Services Market Size, Share & Trends Analysis Report By Molecule (Small, Large), By Test (Bioavailability, Bioequivalance), By Workflow (Sample Analysis, Sample Preparation), And Segment Forecasts, 2022 - 2030 ", published by Grand View Research.
  • The small molecule-based bioanalytical testing services are estimated to hold the highest share over the forecast period.
  • On the other hand, large molecule bioanalytical testing services are expected to grow at the fastest rate during the forecast period.
  • Grand View Research has segmented the global bioanalytical testing services market based on molecule, test, workflow, therapeutic area, end-user, and region:
    Bioanalytical Testing Services Market - Molecule Outlook (Revenue, USD Billion, 2018 - 2030)

Bioanalytical Testing Services Market Worth $7.65 Billion by 2030: Grand View Research, Inc.

Retrieved on: 
Tuesday, October 18, 2022
Molecule, SAN, Revenue, Sony NEX-7, AstraZeneca, Small, GSK, Growth, Vaccine, Organization, CAGR, LC-MS, Bioavailability, GCLP, Services marketing, GlaxoSmithKline, COVID-19, Overalls, Good clinical laboratory practice, COVID-19 vaccine, USD, Fine chemical, Generic drug, Pharmaceutical industry, Bioequivalence, Workflow

Read 165-page market research report, " Bioanalytical Testing Services Market Size, Share & Trends Analysis Report By Molecule (Small, Large), By Test (Bioavailability, Bioequivalance), By Workflow (Sample Analysis, Sample Preparation), And Segment Forecasts, 2022 - 2030 ", published by Grand View Research.

Key Points: 
  • Read 165-page market research report, " Bioanalytical Testing Services Market Size, Share & Trends Analysis Report By Molecule (Small, Large), By Test (Bioavailability, Bioequivalance), By Workflow (Sample Analysis, Sample Preparation), And Segment Forecasts, 2022 - 2030 ", published by Grand View Research.
  • The small molecule-based bioanalytical testing services are estimated to hold the highest share over the forecast period.
  • On the other hand, large molecule bioanalytical testing services are expected to grow at the fastest rate during the forecast period.
  • Grand View Research has segmented the global bioanalytical testing services market based on molecule, test, workflow, therapeutic area, end-user, and region:
    Bioanalytical Testing Services Market - Molecule Outlook (Revenue, USD Billion, 2018 - 2030)

KCAS Expands Its Transatlantic Presence with the Acquisition of France-based Active Biomarkers

Retrieved on: 
Monday, September 12, 2022
Biotechnology, Technology, Other Health, Health, Pharmaceutical, Oncology, Other Science, Other Technology, Research, Genetics, Science, MSD, Partner, Inflammation, PK, Vitruvian Partners, GLP, Infection, ELISA, Luminex, Neurodegeneration, Acquisition, Biomarker, Growth, Partnership, GCLP, Investment, CEO, CRO, BSL2, ELLA, Science, Drug development, KCAS, ISO 9001:2015, Multimedia, Flow cytometry, ISO, ELISpot, Fine chemical, Kansas City metropolitan area, Vitruvian Man

Active Biomarkers is a renowned assay development and specialty bioanalytical laboratory with expertise in oncology, infectious disease, inflammation and neurodegenerative disorders.

Key Points: 
  • Active Biomarkers is a renowned assay development and specialty bioanalytical laboratory with expertise in oncology, infectious disease, inflammation and neurodegenerative disorders.
  • The acquisition of Active Biomarkers is the second in 2022 by KCAS.
  • The acquisition of Active Biomarkers gives our combined clients access to further scientific expertise and support in both markets regionally and internationally.
  • The acquisition of Active Biomarkers by KCAS builds on the excellent foundation KCAS has built in the US and supports the increasingly international needs of the companys growing pharmaceutical and biotech clients.

ProteoNic announces licensing of its premium 2G UNic™ Technology Platform for Production of Biologics to FyoniBio

Retrieved on: 
Tuesday, July 5, 2022
CEO, GEX, Unic, CHO, ISO9001, Immortalised cell line, Proteon Therapeutics, GMP, PK, GCLP, Partnership, Technology, Solution, RCB, Fine chemical

Under the agreement, FyoniBio gains worldwide, non-exclusive commercial rights for application of ProteoNic technology in its proprietary CHOnamite platform.

Key Points: 
  • Under the agreement, FyoniBio gains worldwide, non-exclusive commercial rights for application of ProteoNic technology in its proprietary CHOnamite platform.
  • ProteoNic's premium protein expression technology 2G UNic improves production levels across a range of mammalian cell types, selection systems and product classes.
  • The company offers technology and services for the generation of cell lines with greatly improved biologics production characteristics, including production levels and stability.
  • FyoniBio is part of the Canton Biologics group, a private-funded science-driven enterprise located in the Canton greater Bay area, China.

ProteoNic announces licensing of its premium 2G UNic™ Technology Platform for Production of Biologics to FyoniBio

Retrieved on: 
Tuesday, July 5, 2022
CEO, GEX, Unic, CHO, ISO9001, Immortalised cell line, Proteon Therapeutics, GMP, PK, GCLP, Partnership, Technology, Solution, RCB, Fine chemical

Under the agreement, FyoniBio gains worldwide, non-exclusive commercial rights for application of ProteoNic technology in its proprietary CHOnamite platform.

Key Points: 
  • Under the agreement, FyoniBio gains worldwide, non-exclusive commercial rights for application of ProteoNic technology in its proprietary CHOnamite platform.
  • ProteoNic's premium protein expression technology 2G UNic improves production levels across a range of mammalian cell types, selection systems and product classes.
  • The company offers technology and services for the generation of cell lines with greatly improved biologics production characteristics, including production levels and stability.
  • FyoniBio is part of the Canton Biologics group, a private-funded science-driven enterprise located in the Canton greater Bay area, China.

Glycotope to spin-out its Service Business to the newly formed FyoniBio GmbH

Retrieved on: 
Tuesday, February 1, 2022
CHO, Perfusion, CGMP, CMC, Submarine, GCLP, Technology, GMP, GEX, Vaccine, RCB, Cell biology, Protein, PK, Antibody, Fine chemical

Glycotope has to date discovered in excess of 150 GlycoTargets with antibodies against several of these targets currently under development.

Key Points: 
  • Glycotope has to date discovered in excess of 150 GlycoTargets with antibodies against several of these targets currently under development.
  • Based on their superior tumor-specificity, Glycotope antibodies are suitable for development in an array of different modes of action including naked antibodies, bispecifics, antibody-drug-conjugates, cellular therapies or fusion-proteins.
  • Currently six clinical and pre-clinical programs based on this technology are under development by Glycotope or its licensing partners.
  • FyoniBio is a newly formed contract development and clinical lab company continuing the service business of Glycotope on the biotech campus Berlin Buch.